In Yaroslavl started the production of the drug for the treatment of multiple myeloma

The company “Takeda Russia” announced the receipt of a registration certificate of Ministry of health of the Russian Federation, confirming the right to produce oxazoline for the treatment of patients with multiple myeloma. The production of the drug included in the EDL will be carried out at the company’s plant in Yaroslavl. The total investment in the localization of production totaled 590 million rubles.

The production capacity will meet the demand and EEU in a drug, said the company. The plant in Yaroslavl became the second company in the world for the production of the drug and the stage of the finished dosage form.

Exosomes is a proprietary development of the company, is available in capsule form and is shown in combination with lenalidomide and dexamethasone for patients with multiple myeloma that have previously received at least one line of previous treatment. The drug was registered in Russia in 2017 and launched into the Russian market in 2018.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]